<h4>Purpose</h4>Outcomes of patients with sickle cell disease (SCD) and type 2 diabetes mellitus (T2DM) treated with glucagon-like peptide-1 (GLP1-RA) remain poorly understood. This evidence concerns the gene GLP1R and Schnyder corneal dystrophy.